Integra LifeSciences (NASDAQ:IART) Issues Quarterly Earnings Results

Key Points

• Q1 beat and updated guidance: Integra reported adjusted EPS of $0.54 versus $0.41 expected and revenue of $391.9M, and raised FY2026 adjusted EPS guidance to $2.40–$2.50 while maintaining revenue guidance of $1.66B–$1.70B.
• Leadership shift to sharpen commercial execution: Stuart Essig resumed the CEO role (retaining Chairman) and the company hired Michael McBreen as Chief Commercial Officer to improve commercial execution, culture and customer focus.
• Improving cash flow but near‑term pressure: Q1 operating cash flow rose to $9.8M and management expects ~+$150M vs. 2025 with net debt ~$1.6B and a plan to reduce leverage to 2.5–3.5x by end‑2026, though Q2 EPS (0.44–0.52) and revenue guidance are lighter than consensus.

Integra LifeSciences (NASDAQ:IART - Get Free Report) posted its quarterly earnings data on Tuesday. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.13, FiscalAI reports. The firm had revenue of $391.92 million during the quarter, compared to analysts' expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.41 EPS. Integra LifeSciences updated its FY 2026 guidance to 2.400-2.500 EPS and its Q2 2026 guidance to 0.440-0.520 EPS.

Here are the key takeaways from Integra LifeSciences' conference call:

• Leadership change: Stuart Essig has resumed the CEO role (retaining Chairman) with a long-term commitment and the company added Michael McBreen as Chief Commercial Officer to sharpen commercial execution, culture, and customer focus.
• Q1 beat and updated EPS guide: Q1 revenue was $392M and adjusted EPS $0.54 (above guidance); company maintained 2026 revenue guidance of $1.66B–$1.70B and raised full-year adjusted EPS to $2.40–$2.50, citing tariff benefits and operational improvements.
• Tissue Reconstruction momentum and reimbursement positioning: Tissue Reconstruction grew ~6.4% organic (strong Integra Skin, DermaClose, PriMatrix), and management says ~90% of wound reconstruction revenue is inpatient (not impacted by new CMS outpatient skin substitute rules) with the portfolio priced to compete under the new reimbursement framework.
• Quality, supply and product returns: The Compliance Master Plan remediation is progressing with improving supply reliability and Braintree production expected by end of June, but management says the 2026 guide does not rely on meaningful contribution from products still off-market.
• Cash flow and leverage path: Q1 operating cash flow improved to $9.8M, the company expects ~+$150M in operating cash flow vs. 2025, reports net debt of $1.6B and a 4.1x leverage ratio with a plan to approach target leverage of 2.5x–3.5x by end of 2026.

Integra LifeSciences Price Performance

Shares of IART opened at $13.17 on Tuesday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The company has a market cap of $1.03 billion, a P/E ratio of -1.84 and a beta of 1.08. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $16.49. The stock has a fifty day moving average price of $10.09 and a 200 day moving average price of $11.73.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.54 vs. $0.41 est; revenue $391.9M vs. $381.8M est, showing modest year-over-year growth and operating momentum. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Positive Sentiment: Full-year FY2026 EPS guidance raised to $2.40–2.50, above consensus (~$2.35), signaling management confidence in longer‑term profitability despite near-term headwinds. FY2026 Guidance in Press Release
• Neutral Sentiment: Leadership transition announced — Stuart Essig named President & CEO and Michael McBreen appointed Chief Commercial Officer; this provides clarity on succession but will take time to assess strategic impact. Leadership Transition Announcement
• Negative Sentiment: Near-term guidance came in light — Q2 EPS guide $0.440–0.520 (consensus ~$0.53) and revenue guide $410M–$425M (consensus ~$425.3M), which could pressure near-term estimates and cap upside until mid‑year results. Q2 Guidance in Press Release

Institutional Trading of Integra LifeSciences

A number of large investors have recently modified their holdings of the company. Corient Private Wealth LLC bought a new position in Integra LifeSciences in the 4th quarter worth about $189,000. Virtu Financial LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $124,000. Invesco Ltd. boosted its position in shares of Integra LifeSciences by 0.9% during the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company's stock worth $43,754,000 after buying an additional 31,931 shares during the period. State of Tennessee Department of Treasury grew its holdings in Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company's stock worth $332,000 after buying an additional 1,964 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Integra LifeSciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 1,353,467 shares of the life sciences company's stock valued at $16,810,000 after acquiring an additional 32,192 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IART. Truist Financial lowered their price objective on Integra LifeSciences from $13.00 to $12.00 and set a "hold" rating for the company in a report on Wednesday, April 15th. Wells Fargo & Company upgraded Integra LifeSciences to a "hold" rating in a report on Wednesday, March 18th. Wall Street Zen cut Integra LifeSciences from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Argus reaffirmed a "hold" rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Finally, Citigroup dropped their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a "sell" rating on the stock in a report on Wednesday, March 11th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Reduce" and a consensus price target of $14.20.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.